company background image
ORY logo

Oryzon Genomics BME:ORY Stock Report

Last Price

€1.91

Market Cap

€110.0m

7D

-2.9%

1Y

-8.6%

Updated

21 Jul, 2024

Data

Company Financials +

ORY Stock Overview

A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.

ORY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Oryzon Genomics S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oryzon Genomics
Historical stock prices
Current Share Price€1.91
52 Week High€2.39
52 Week Low€1.55
Beta0.63
11 Month Change1.27%
3 Month Change-3.54%
1 Year Change-8.61%
33 Year Change-45.58%
5 Year Change-36.33%
Change since IPO-58.48%

Recent News & Updates

Recent updates

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Jun 09
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Apr 04
Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Jul 24
Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

May 01
Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Feb 26
Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Jan 04
If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Shareholder Returns

ORYES BiotechsES Market
7D-2.9%-5.7%-1.5%
1Y-8.6%-27.6%13.3%

Return vs Industry: ORY exceeded the Spanish Biotechs industry which returned -27.6% over the past year.

Return vs Market: ORY underperformed the Spanish Market which returned 13.3% over the past year.

Price Volatility

Is ORY's price volatile compared to industry and market?
ORY volatility
ORY Average Weekly Movement4.3%
Biotechs Industry Average Movement7.6%
Market Average Movement3.0%
10% most volatile stocks in ES Market6.0%
10% least volatile stocks in ES Market0.7%

Stable Share Price: ORY has not had significant price volatility in the past 3 months.

Volatility Over Time: ORY's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of Spanish stocks.

About the Company

FoundedEmployeesCEOWebsite
200043Carlos Manuel Arjolwww.oryzon.com

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.

Oryzon Genomics S.A. Fundamentals Summary

How do Oryzon Genomics's earnings and revenue compare to its market cap?
ORY fundamental statistics
Market cap€110.04m
Earnings (TTM)-€2.92m
Revenue (TTM)n/a

0.0x

P/S Ratio

-37.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$3.17m
Earnings-US$3.17m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.055
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio24.8%

How did ORY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.